Oaktree Capital Management is a privately owned investment manager specializing in alternative investment strategies.
Business Model:
Revenue: $709.5M
Employees: 1,001-5,000
Oaktree Capital Management was acquired by
Brookfield Asset Management.
The acquisition happend on 2019-03-13.
Details of the transaction were not public
Address: 333 South Grand Avenue
City: Los Angeles
State: CA
Zip: 90071
Country: US
Oaktree’s mission is to provide highly professional management with a primary emphasis on risk control in a limited number of sophisticated investment specialties. Oaktree specializes in less efficient markets and alternative investments, and has extensive experience, an enviable track record, broad product range and substantial assets under management. They are dedicated to the achievement of consistent and superior performance without high risk. Their ultimate objective is investment success, the fruits of which are shared by Oaktree’s clients and personnel.
Contact Phone:
+12138306300
Contact Email:
Listed Exchange:
NYSE
IPO Date:
4/12/2012
IPO Valuation:
$1B
Ticker Symbol:
OAK
IPO Price:
$43/share
Amount Raised:
$380M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2022 | Impel NeuroPharma | Post-IPO Debt | 50M |
4/2020 | Airbnb | Debt Financing | 1B |
2/2022 | Draslovka | Private Equity Round | 0 |
3/2013 | Charter Communications | Post-IPO Equity | - |
12/2021 | Montana Renewables | Debt Financing | 300M |
9/2021 | Priority Power Management | Private Equity Round | 250M |
11/2020 | REEF | Private Equity Round | 700M |
6/2019 | cure.fit | Series D | 120M |
4/2022 | BioXcel Therapeutics | Post-IPO Debt | 135M |
12/2021 | SiO2 Materials Science | Debt | 205M |
12/2020 | BKV Corporation | Venture Round | 100M |
7/2020 | M3M India Limited | Debt Financing | 76M |
12/2020 | brumbrum | Debt Financing | 65M |
6/2021 | Primary Wave | Private Equity Round | - |
9/2016 | ICICI Prudential Life Insurance | Private Equity Round | 0 |
8/2020 | Fortress Biotech | Post-IPO Debt | 60M |
7/2016 | Array Technologies | Seed Round | - |
3/2021 | SumUp | Debt Financing | 0 |
10/2011 | Panrico SA | Debt Financing | - |
3/2021 | NN | Post-IPO Equity | 265M |
4/2014 | Enplug | Seed Round | 0 |
11/2016 | Sterling Lumber Company | Venture Round | - |
10/2021 | Thrasio | Series D | 0 |
3/2021 | RumbleON | Post-IPO Equity | 280M |
3/2016 | ProService Finteco | Private Equity Round | - |
7/2018 | cure.fit | Series C | 120M |
1/2022 | Unblocked | Seed Round | 0 |
10/2018 | Montrose | Private Equity Round | - |
2/2018 | Kudu Investment Management | Funding Round | 0 |
6/2004 | Infraworks | Series B | 7.5M |
9/2020 | Zzoomm Full Fibre Broadband | Series B | 128.7M |
2/2021 | Thrasio | Series C | 750M |
4/2021 | Thrasio | Series C | 0 |
10/2022 | scPharmaceuticals | Post-IPO Debt | 100M |
10/2016 | SunOpta | Post-IPO Equity | 85M |
4/2020 | SunOpta | Post-IPO Equity | 0 |
4/2015 | ezbob | Debt Financing | 45.2M |
1/2014 | Ten K Solar | Venture Round | 0 |
9/2020 | Universal Plant Services | Secondary Market | - |
9/2019 | Mission Lane | Debt Financing | 300M |
8/2021 | Environmental 360 Solutions E360S | Venture Round | - |
7/2019 | Singular | Venture Round | - |
6/2019 | Costa Edutainment | Secondary Market | 45.5M |
12/2021 | Cvent | Post-IPO Equity | 0 |
10/2018 | Assembled Brands | Funding Round | 100M |
10/2018 | Blue Sky Private Equity | Post-IPO Debt | 35.9M |
4/2022 | BioXcel Therapeutics | Post-IPO Equity | 5M |
11/2012 | Pulse Electronics | Post-IPO Equity | 102.7M |
11/2021 | Elevate Brands | Venture Round | 0 |
12/2021 | HealthCare.com | Series C | 0 |
2/2021 | Win Brands Group | Equity | 50M |
7/2017 | DDH1 | Venture Round | - |
12/2020 | System One | Private Equity Round | - |
1/2021 | Thrasio | Debt Financing | 0 |
3/2016 | FortiFi | Series A | 75M |
3/2016 | ezbob | Series C | 28.8M |
3/2018 | Proserv | Private Equity Round | 50M |
6/2016 | Tribes | Venture Round | - |
5/2021 | Marinus Pharmaceuticals | Post-IPO Debt | 45M |
2/2022 | b atomic | Seed | 1M |
10/2021 | Mission Lane | Debt Financing | 150M |
12/2019 | Marinus Pharmaceuticals | Equity | 30M |
6/2019 | SHINE Medical Technologies | Debt | 50M |
1/2022 | ABC Technologies | Post-IPO Equity | 269.5M |
4/2022 | BioXcel Therapeutics | Post-IPO Debt | 0 |
4/2022 | BioXcel Therapeutics | Post-IPO Equity | 0 |
3/2022 | Marinus Pharmaceuticals | Post-IPO Debt | 0 |
3/2022 | Impel NeuroPharma | Post-IPO Debt | 0 |
2/2022 | b atomic | Seed Round | 0 |
2/2022 | Draslovka | Private Equity Round | 0 |
1/2022 | Unblocked | Seed Round | 0 |
1/2022 | ABC Technologies | Post-IPO Equity | 0 |
12/2021 | SiO2 Materials Science | Debt Financing | 0 |
12/2021 | HealthCare.com | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|